1 Min Read
NEW YORK (Reuters) - Drugmaker Mylan Inc (MYL.O), which is trying to launch a generic form of GlaxoSmithKline's (GSK.L) Advair asthma treatment, on Wednesday said it is in disagreement with the U.S. Food and Drug Administration over the standards it must meet.
The FDA sent Mylan a letter earlier this year in which it declined to approve the product, but the company had not previously disclosed the issues at hand. Mylan declined to set a timeline for launch for the product.
Reporting by Caroline Humer; Editing by Chizu Nomiyama